Navigation Links
BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results
Date:3/17/2009

($ amounts in thousands) December 31, December 31, 2008 2007 Assets Current Assets: Cash and Cash Equivalents $15,740 $22,837 Restricted Cash 1,150 1,297 Notes Receivable 15,797 -- Accounts Receivable, net of allowance for doubtful accounts of $51 and $44 30,897 11,707 Inventory, net of allowance for obsolescence of $0 10,184 2,897 Due from Related Party 1,834 -- Other Receivables 2,168 1,379 VAT Receivable 921 828 Prepaid Expenses and Other Current Assets 6,247 2,444 Total Current Assets 84,938 43,389 Property and Equipment, net 22,840 745 Investment in Sunstone China Limited -- 33,126 Investment in Alliance BMP 15,093 2,773 Investments, at Cost 146 137 Goodwill 69,866 -- Other Assets 875 280 Land Use Rights, net of accumulated amortization 2,002 -- Intangible Assets, net of accumulated amortization 41,891 473 Total Assets $237,651 $80,923 Liabilities and Stockholders' Equity Cur
'/>"/>
SOURCE BMP Sunstone Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. BMP Sunstone to Present at UBS Global Healthcare Services Conference
2. BMP Sunstone Adopts Voluntary Executive Compensation Restrictions in 2008 and 2009
3. BMP Sunstone Receives High Tech Status
4. BMP Sunstone to Present at the 20th Annual Piper Jaffray Health Care Conference
5. BMP Sunstone Acquires Runchang Capsule and Related LFHC Technology
6. BMP Sunstone to Host Follow-Up 3Q08 Conference Call Due to Technical Difficulties Encountered on Tuesdays Call
7. BMP Sunstone Reports Third Quarter 2008 Financial Results
8. BMP Sunstone Announces Participation in November Investor Conferences
9. BMP Sunstone Announces Participation in September Investor Conference
10. BMP Sunstone Receives Production License from the SFDA to Manufacture and Market Pediatric Multivitamin Granules in the PRC
11. BMP Sunstone Reports Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... March 30, 2015  Naldemedine, an investigational peripherally ... Shionogi & Co., Ltd., met its primary and ... I) for the treatment of opioid-induced constipation (OIC) ... opioid therapy. Study results showed that naldemedine (0.2 ... the frequency of spontaneous bowel movement (SBM) compared ...
(Date:3/29/2015)... March 29, 2015 Caris Life ... study data showing the presence of PD-1 ... cancer samples. Using Caris Molecular Intelligence®, the ... identified expression of programmed cell death protein-1 ... histology while its ligand (PD-L1) expression was ...
(Date:3/27/2015)... LANSING, Mich. , March 27, 2015  Neogen ... Properties, LLC, has adopted a prearranged trading plan in ... James Herbert , Chairman and CEO of Neogen Corporation, ... shares of Neogen Corporation common stock. Herbert ... the disclosure was appropriate. The filing is only for ...
(Date:3/27/2015)... 2015  CASI Pharmaceuticals, Inc. (Nasdaq: CASI ), ... commercialization of innovative therapeutics addressing cancer and other unmet ... focus on China , today reported ... December 31, 2014.  The Company reported ... share, for the three months ended December 31, 2014.  ...
Breaking Biology Technology:Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 2Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 3Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 4Neogen CEO adopts 10b5-1 Trading Plan 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 3CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 4CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 5CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 6
... Mass., Jan. 9, 2012  Idenix Pharmaceuticals, Inc. (NASDAQ: ... discovery and development of drugs for the treatment of ... hepatitis C virus (HCV) development pipeline. ... of a phase I clinical trial of the Company,s ...
... 9, 2012 , Collaboration to create ... to active TB, enabling early treatment and disease outbreak prevention ... infectious disease portfolio with development of DNA-/RNA-based test that complements ... , New assay will use whole blood transcription profiling ...
... FRANCISCO, Jan. 7, 2012 Sutro Biopharma, a biopharmaceutical ... pharmaceutical properties, today announced that it has appointed James ... its newly formed scientific advisory board (SAB).  Prof. Wells ... "We have brought together two leading scientific experts in ...
Cached Biology Technology:Idenix Reports Advancement of HCV Development Pipeline 2Idenix Reports Advancement of HCV Development Pipeline 3Idenix Reports Advancement of HCV Development Pipeline 4QIAGEN and Max Planck Institute for Infection Biology Collaborate to Develop Assay for Active TB Risk in Individuals With Latent Infection 2QIAGEN and Max Planck Institute for Infection Biology Collaborate to Develop Assay for Active TB Risk in Individuals With Latent Infection 3QIAGEN and Max Planck Institute for Infection Biology Collaborate to Develop Assay for Active TB Risk in Individuals With Latent Infection 4QIAGEN and Max Planck Institute for Infection Biology Collaborate to Develop Assay for Active TB Risk in Individuals With Latent Infection 5QIAGEN and Max Planck Institute for Infection Biology Collaborate to Develop Assay for Active TB Risk in Individuals With Latent Infection 6QIAGEN and Max Planck Institute for Infection Biology Collaborate to Develop Assay for Active TB Risk in Individuals With Latent Infection 7Sutro Announces Newly Formed Scientific Advisory Board 2Sutro Announces Newly Formed Scientific Advisory Board 3
(Date:3/17/2015)... , March 17, 2015 ... company specializing in clinical study management systems, is ... in attendance at ARENA,s Outsourcing in Clinical Trials ... This event provides an excellent forum for MedNet ... flexible and affordable software-as-a-service (SaaS) eClinical technology platform. ...
(Date:3/12/2015)... , March 12, 2015 The mascots ... Brenner Children,s Hospital, part of Wake Forest Baptist Medical ... initiative for the 2015 ACC Men,s Basketball Tournament. Young ... with them and getting their autographs. Brenner ... Baptist. It is the only children,s hospital in northwest ...
(Date:3/10/2015)... , March 10, 2015  Continuing its 167-year history ... Hammacher Schlemmer introduces The Eye Scanning Password Authenticator ... granting access to secure websites or sensitive data. ... travelers at international borders, the device has a small ... points of the iris, converting them into an encrypted ...
Breaking Biology News(10 mins):Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2
... After every meal, the body must prevent the immune ... researchers report the identity of a nutrient "floodgate" that ... Their findings appear in the May 4, 2007 issue ... , The researchers found that animals lacking a protein ...
... body appears to control whether certain medications, such as ... or in inhalers for asthma, lose their effectiveness over ... the body that controls many functions, including the contraction ... conducted by Duke University Medical Center and Howard Hughes ...
... diabetic patients of the superbug MRSA - by treating ... and his team used green bottle fly larvae to ... with MRSA and found all but one were cured ... than the 28-week duration for the conventional treatment. ...
Cached Biology News:Keeping the immune system from starting a 'food fight' 2Nitric oxide: Key to cardiovascular and pulmonary function and drug effectiveness 2Nitric oxide: Key to cardiovascular and pulmonary function and drug effectiveness 3Maggots rid patients of MRSA 2
A set of five peptides which can be used to calibrate a Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) or Electrospray Ionization (ESI) mass spectrometer....
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. ID clarifier: cap, ...
... Pre-tested for optimal ... support the growth of ... for methylcellulose colony-forming assays ... hematopoietic cells. Not suitable ...
... RAW 264. 7 cells were cultured in DMEM ... the log phase of growth. In order ... cells were fixed in acetone-methanol. The cells ... coated slide, with each wells surface specifically treated ...
Biology Products: